Literature DB >> 23469314

Improving outcomes in multiple sclerosis through early diagnosis and effective management.

Emmanuelle Waubant.   

Abstract

Entities:  

Year:  2012        PMID： 23469314      PMCID： PMC3583755          DOI： 10.4088/PCC.11016co2cc

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN： 2155-7780


× No keyword cloud information.
  28 in total

Review 1.  The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes.

Authors:  M Trojano; D Paolicelli
Journal:  Neurol Sci       Date:  2001-11       Impact factor: 3.307

Review 2.  Managing the symptoms of multiple sclerosis: a multimodal approach.

Authors:  Heidi J Crayton; Howard S Rossman
Journal:  Clin Ther       Date:  2006-04       Impact factor: 3.393

3.  A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

Authors:  B G Weinshenker; P C O'Brien; T M Petterson; J H Noseworthy; C F Lucchinetti; D W Dodick; A A Pineda; L N Stevens; M Rodriguez
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

4.  Plasma exchange for severe attacks of CNS demyelination: predictors of response.

Authors:  M Keegan; A A Pineda; R L McClelland; C H Darby; M Rodriguez; B G Weinshenker
Journal:  Neurology       Date:  2002-01-08       Impact factor: 9.910

Review 5.  Exercise therapy for multiple sclerosis.

Authors:  M B Rietberg; D Brooks; B M J Uitdehaag; G Kwakkel
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

Review 6.  The differential diagnosis of multiple sclerosis.

Authors:  Loren A Rolak; John O Fleming
Journal:  Neurologist       Date:  2007-03       Impact factor: 1.398

7.  Mycophenolate mofetil in multiple sclerosis.

Authors:  Elliot M Frohman; Kristen Brannon; Michael K Racke; Kathleen Hawker
Journal:  Clin Neuropharmacol       Date:  2004 Mar-Apr       Impact factor: 1.592

8.  Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses.

Authors:  L La Mantia; M Eoli; C Milanese; A Salmaggi; A Dufour; V Torri
Journal:  Eur Neurol       Date:  1994       Impact factor: 1.710

9.  Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.

Authors:  Ludwig Kappos; Mark S Freedman; Chris H Polman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Frederik Barkhof; Ernst-Wilhelm Radü; Lars Bauer; Susanne Dahms; Vivian Lanius; Christoph Pohl; Rupert Sandbrink
Journal:  Lancet       Date:  2007-08-04       Impact factor: 79.321

10.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.